Continuous vs Bolus Thermodilution to Assess Microvascular Resistance Reserve.


Journal

JACC. Cardiovascular interventions
ISSN: 1876-7605
Titre abrégé: JACC Cardiovasc Interv
Pays: United States
ID NLM: 101467004

Informations de publication

Date de publication:
27 Nov 2023
Historique:
received: 29 05 2023
revised: 14 09 2023
accepted: 19 09 2023
medline: 1 12 2023
pubmed: 30 11 2023
entrez: 29 11 2023
Statut: ppublish

Résumé

Coronary flow reserve (CFR) and microvascular resistance reserve (MRR) can, in principle, be derived by any method assessing coronary flow. The aim of this study was to compare CFR and MRR as derived by continuous (CFR A total of 175 patients with chest pain and nonobstructive coronary artery disease were studied. Bolus and continuous thermodilution measurements were performed in the left anterior descending coronary artery. MRR was calculated as the ratio of CFR to fractional flow reserve and corrected for changes in systemic pressure. In 102 patients, bolus and continuous thermodilution measurements were performed in duplicate to assess test-retest reliability. Mean CFR Compared with bolus thermodilution, continuous thermodilution yields lower values of CFR and MRR accompanied by an almost 3-fold reduction of the variability in the measured results.

Sections du résumé

BACKGROUND BACKGROUND
Coronary flow reserve (CFR) and microvascular resistance reserve (MRR) can, in principle, be derived by any method assessing coronary flow.
OBJECTIVES OBJECTIVE
The aim of this study was to compare CFR and MRR as derived by continuous (CFR
METHODS METHODS
A total of 175 patients with chest pain and nonobstructive coronary artery disease were studied. Bolus and continuous thermodilution measurements were performed in the left anterior descending coronary artery. MRR was calculated as the ratio of CFR to fractional flow reserve and corrected for changes in systemic pressure. In 102 patients, bolus and continuous thermodilution measurements were performed in duplicate to assess test-retest reliability.
RESULTS RESULTS
Mean CFR
CONCLUSIONS CONCLUSIONS
Compared with bolus thermodilution, continuous thermodilution yields lower values of CFR and MRR accompanied by an almost 3-fold reduction of the variability in the measured results.

Identifiants

pubmed: 38030361
pii: S1936-8798(23)01322-5
doi: 10.1016/j.jcin.2023.09.027
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

2767-2777

Informations de copyright

Copyright © 2023 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Funding Support and Author Disclosures Drs Paolisso and Esposito are supported by a research grant from the CardioPaTh PhD Program. Dr Barbato has received speaker fees from Abbott Vascular, Boston Scientific, and GE Healthcare. Dr Collet has received research grants from Biosensors, GE Healthcare, Medis Medical Imaging, Pie Medical Imaging, CathWorks, Boston Scientific, Siemens, HeartFlow, and Abbott Vascular; and has received consultancy fees from HeartFlow, Opsens, Pie Medical Imaging, Abbott Vascular, and Philips. Dr De Bruyne has institutional consulting relationships with Boston Scientific, Abbott Vascular, CathWorks, Siemens, GE Healthcare, and Coroventis Research; has received institutional research grants from Abbott Vascular, Coroventis Research, CathWorks, and Boston Scientific; and has minor equity holdings in Philips, Siemens, GE Healthcare, Edwards Lifesciences, HeartFlow, Opsens, Celiad, Bayer, and Sanofi. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.

Auteurs

Emanuele Gallinoro (E)

Cardiovascular Center Aalst, OLV-Clinic, Aalst, Belgium; Division of University Cardiology, IRCCS Galeazzi - Sant'Ambrogio Hospital, Milan, Italy.

Dario Tino Bertolone (DT)

Cardiovascular Center Aalst, OLV-Clinic, Aalst, Belgium; Department of Advanced Biomedical Sciences, University Federico II, Naples, Italy.

Takuya Mizukami (T)

Cardiovascular Center Aalst, OLV-Clinic, Aalst, Belgium; Division of Clinical Pharmacology, Department of Pharmacology, Showa University, Tokyo, Japan.

Pasquale Paolisso (P)

Cardiovascular Center Aalst, OLV-Clinic, Aalst, Belgium; Department of Advanced Biomedical Sciences, University Federico II, Naples, Italy.

Konstantinos Bermpeis (K)

Cardiovascular Center Aalst, OLV-Clinic, Aalst, Belgium.

Daniel Munhoz (D)

Cardiovascular Center Aalst, OLV-Clinic, Aalst, Belgium.

Koshiro Sakai (K)

Cardiovascular Center Aalst, OLV-Clinic, Aalst, Belgium.

Ruiko Seki (R)

Cardiovascular Center Aalst, OLV-Clinic, Aalst, Belgium.

Hirofumi Ohashi (H)

Cardiovascular Center Aalst, OLV-Clinic, Aalst, Belgium.

Giuseppe Esposito (G)

Cardiovascular Center Aalst, OLV-Clinic, Aalst, Belgium; Department of Advanced Biomedical Sciences, University Federico II, Naples, Italy.

Serena Caglioni (S)

Cardiovascular Center Aalst, OLV-Clinic, Aalst, Belgium.

Niya Mileva (N)

Cardiovascular Center Aalst, OLV-Clinic, Aalst, Belgium.

Attilio Leone (A)

Cardiovascular Center Aalst, OLV-Clinic, Aalst, Belgium.

Alessandro Candreva (A)

Cardiovascular Center Aalst, OLV-Clinic, Aalst, Belgium; Department of Cardiology, Zurich University Hospital, Zurich, Switzerland; PoliTo(BIO) Med Lab, Department of Mechanical and Aerospace Engineering, Politecnico di Torino, Turin, Italy.

Marta Belmonte (M)

Cardiovascular Center Aalst, OLV-Clinic, Aalst, Belgium.

Tatyana Storozhenko (T)

Cardiovascular Center Aalst, OLV-Clinic, Aalst, Belgium.

Michele Mattia Viscusi (MM)

Cardiovascular Center Aalst, OLV-Clinic, Aalst, Belgium.

Marc Vanderheyden (M)

Cardiovascular Center Aalst, OLV-Clinic, Aalst, Belgium.

Eric Wyffels (E)

Cardiovascular Center Aalst, OLV-Clinic, Aalst, Belgium.

Jozef Bartunek (J)

Cardiovascular Center Aalst, OLV-Clinic, Aalst, Belgium.

Jeroen Sonck (J)

Cardiovascular Center Aalst, OLV-Clinic, Aalst, Belgium.

Emanuele Barbato (E)

Cardiovascular Center Aalst, OLV-Clinic, Aalst, Belgium; Department of Clinical and Molecular Medicine, Sapienza University, Rome, Italy.

Carlos Collet (C)

Cardiovascular Center Aalst, OLV-Clinic, Aalst, Belgium.

Bernard De Bruyne (B)

Cardiovascular Center Aalst, OLV-Clinic, Aalst, Belgium; Department of Cardiology, Lausanne University Hospital, Lausanne, Switzerland. Electronic address: bernard.de.bruyne@olvz-aalst.be.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH